IP Roundup: Philadelphia Health and Education Corporation, Illumina, Canon, Biosigma, Affymetrix | GenomeWeb

Philadelphia Health and Education Corporation of Philadelphia has received US Patent No. 8,206,899, "Prostate cancer-related compositions, methods and kits based on DNA microarray proteomics platforms." Methods of detecting and treating prostate cancer are claimed that include modulating or detecting PCADM-1 gene expression and the production and activity of the PCADM-1 polypeptide. Arrays are also claimed for the identification of DNA-binding proteins and the double-stranded oligonucleotide sequences that specifically bind with them.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Biomedical research projects are generating a ton of data that still needs to be analyzed, NPR reports.

Theranos is retiring some of its board members, including Henry Kissinger and George Shultz, Business Insider reports.

The heads of 29 scientific societies and some 2,300 researchers call on President-elect Donald Trump to rely on and support science in two separate letters.

In Science this week: genetically modified flu virus could be key to new live vaccines, and more.